Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.38 |
| ▸ | PPARD | Q03181 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15969110 | 0.92 | S1PR5 (0.40) | TLR9TLR8TLR7FFAR4S1PR5 | |
| SCHEMBL15968836 | 0.88 | KMO (0.46) | FFAR4S1PR5S1PR1GRM2KMO | |
| SCHEMBL15968096 | 0.82 | S1PR5 (0.38) | TLR9TLR8TLR7FFAR4S1PR5 | |
| SCHEMBL15968391 | 0.79 | KMO (0.46) | FFAR4S1PR5S1PR1GRM2KMO | |
| SCHEMBL15968124 | 0.78 | TLR9 (0.36) | TLR9TLR8TLR7FFAR4S1PR5 | |
| SCHEMBL15968752 | 0.78 | ACACB (0.48) | — | |
| SCHEMBL15968721 | 0.78 | FKBP1A (0.39) | FFAR4S1PR5S1PR1S1PR3GRM2 | |
| SCHEMBL15968553 | 0.77 | S1PR5 (0.35) | TLR9TLR8TLR7FFAR4S1PR5 | |
| SCHEMBL15969123 | 0.77 | S1PR5 (0.40) | TLR9TLR8TLR7FFAR4S1PR5 | |
| SCHEMBL15969483 | 0.76 | S1PR5 (0.38) | TLR9TLR8TLR7FFAR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | TLR9 3899/4885TLR8 2965/4885TLR7 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.